AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in patients with advanced non-small cell lung cancer.
Ceralasertib is an oral ATR kinase inhibitor designed to enhance anti-tumor immune activity, while Imfinzi is a PD-L1 inhibitor approved for multiple lung and other cancers. AstraZeneca said the combination was generally well tolerated and that no new safety concerns were identified, according to a Dec. 22 news release from the company.
The global trial enrolled 594 patients across more than 20 countries. It studied patients with locally advanced or metastatic non-small cell lung cancer without actionable genomic alterations whose disease had progressed following immunotherapy and platinum-based chemotherapy. Participants were randomized to receive ceralasertib and Imfinzi or standard-of-care docetaxel.
